Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT: Re deflategate
My question is since both teams played with the same balls, why was this an advantage for the Patriots?
Once their supply of pseudo science, misunderstood statistics and just plain BS is exhausted, expect a dose of their ultimate weapon: you're arguing so persistently and persuasively because you're part of the vast conspiracy against them—big pharma, hedge funds, mysterious saboteurs, aliens...
I apologize for my poor communication, no offense meant. I honestly wasn't suggesting that your investing style is based on going contrary to any one person, I know that you're more experienced and knowledgeable than that.
I was just observing that in my own business career, I've seen many people make decisions using that criterion and though it may occasionally work out, it's not quite logical.
I enjoy the give and take between you and Dew, and learn something from both of you.
OT: Dew, it’s your board and of course you can post what you wish. And JQ, you’re certainly one of the most respected scientists on the board. I continue to enjoy and learn from both of you.
But in my incredibly humble opinion, continuing to attempt logical and reasonable dialogue with PPHM followers is futile, annoying, and lowers the usual and expected fact-based tone of the board. It's just a waste of time, or as you like to say Dew, bandwidth.
Churchill said, "A fanatic is one who can't change his mind and won't change the subject." That about sums it up.
Not easy to hang on when things like this happen, easy to understand how one could sell at a loss and move on.
IMHO this will break out this coming week or next.
Best of luck to all.
As a companion piece, this short article:
With oil prices’ plunge, boom fades in some North Dakota towns
http://www.dispatch.com/content/stories/national_world/2015/01/11/with-oil-prices-plunge-boom-fades-in-some-north-dakota-towns.html
I lived in North Dakota for a few years. People say that New Englanders have a certain laconically cynical attitude, but they've got nothing on the typical North Dakota farmer. I can hear the old timers sitting around saying, "I told you so."
Goncalves has said that the biggest problem has been the Canadian government's failure to build the necessary rail infrastructure. Combined with the current iron ore price, how would another company succeed where Cliffs has failed?
Two more Tweets:
My Oyster ?@OysterX 28m28 minutes ago
$KBIO strong technical close today with a bullish hammer on the daily and a market cap that gives you all of KBIO's tech & products for free
Pete Stock ?@PeteStock11 2h2 hours ago
$KBIO cash per share 1.49 Q32013 vs 0.45 entry today and weekly range after drop of 0.43--.53, Would look to sell around 0.75-.80
Don't follow SPHS, KBIO far from it.
From Twitter, a few minutes ago:
Nick zheng ?@pick1998_2 14m14 minutes ago
$SPHS will be more like to do r-merger since little, if any, option left. $KBIO has a promising mAb at phase II portion, data due June.
Tony Friedman ?@zzlangerhans 12m12 minutes ago
@pick1998_2 Interesting that $SPHS and $KBIO not up on $RGDO news, guess no one but you and I sees a connection.
Nick zheng ?@pick1998_2 4m4 minutes ago
@zzlangerhans :) delayed reaction, inefficient market, or you and I are prescient?
CNAT- FWIW, took a decent-sized position today. Great price, couldn't resist.
Bucks win it all! My post from August: #msg-105275191
I know that the following statement will cause some incredulous groans if not outright laughter, but I bought a boatload of KBIO at $0.50.
$0.60 will give me 20% and I think that's very reachable short term.
Charlie-
Just a couple of points:
1. Many iHubbers think that screaming in all caps makes them seem like confident and knowledgeable experts (if not intimidating bullies.) They don't realize that anything written in all caps is difficult and unpleasant to read, and constant screaming is just silly and soon ignored. They should cut it out.
2. Like most boards, most of the readers here are long-time holders who don't post or post very occasionally. A lot of them just lost a lot of money. If the drive-by self-proclaimed experts can't show any humility at least they can show a little normal human compassion. Stop those stupid obnoxious phony bwahaha's and LOL's and stop calling people names.
PBR up 10% (under $6 was just too good to pass up), some of the smaller producers about the same.
I'm not saying that the carnage is definitely over, but perhaps investors are realizing that there are some great sale prices out there.
Lot't of craziness in the last few minutes. I've got the close at 0.5199. Can anyone corroborate?
PBR: FWIW, averaged-up a bit this morning, now have a fair-sized position at $6. Should be interesting!
They couldn't even find a subgroup where their failed drug worked (so spin the PR into something that seems positive) which is very unusual in biotech. Also second big failure.
Again, you guys are great at pure ticker symbol trading and this could be a money maker on that level, but scientifically KBIO is toast.
Can't post on other board, so: 2 other drugs are years away from any possible commercialization, and they also might be busts. Drug that failed was their baby.
Might be a technical bounce play...you guys are good at that...but fundamental DD-wise, they're dead in the water.
PBR: FWIW took a small position today at $5.90, couldn't resist. Certainly a risk, we'll see.
I think that the results will be favorable, but I won't be holding through.
With some exceptions, the old pattern was a moderate run-up pre-results, then boom or bust depending. The new pattern (last few years) is huge run-up pre, then bust no matter what.
Look at what a simple PR about attending a conference is doing to the price this morning. A little silly, but fine with me.
I have a good-sized position. Almost sold today for a nice profit, but I asked myself that well-known question: would I buy this stock at the current price?
The answer was yes. I'm going to continue to hold, IMHO this still has room to run.
Best of luck.
PBR debt is basically Brazilian national debt: Dilma ensured her re-election by deliberately incurring that debt.
Dew has been saying for years that sooner or later the government will simply drop the charade and nationalize the company. Perhaps, but I don't think so.
Oil will rebound. Buying PBR at a decades-low price for a 5-year hold is hard to resist.
Just on Twitter:
PBR- If this goes below $6 I'm going to have a hard time not buying, although it might be against my better judgement. Just seems incredible.
ANTB - In @ $1.30. Very low float.
Also holding large position of CUR & PSTI from last week.
Very glad I sold all BCLI on Friday: seemed obvious that the run-up was over.
EPRS- Been on my watch list for awhile. One concern for me is the volume, only 23K daily average. Would be tricky to buy in size.
EPRS: Dew, why didn't they just IPO instead of merging with ZLCS?
Perhaps it's hindsight, but wouldn't they have been better off beginning fresh at a decent IPO price rather than RM'ing at $11 and drifting down to $5 or $6?
PIPER $ACHN Price Weakness Offers Buying Opportunity; Reiterate Overweight
Shares of ACHN traded down $3.65 or 23.6% yesterday due to a competitor downgrade
and fueled by year-end profit taking. We believe this sell-off is overblown and are buyers
on weakness. Earlier this weak, new Phase I data showed that Achillion's nuc ACH-3422
was safe and achieved an impressive 4.8 log viral load reduction at 700mg after 14 days of
monotherapy. Achillion also reported interim Phase II data showing that NS5A inhibitor
ACH-3102 + Gilead's Sovaldi achieved 100% SVR4 after only 6 weeks of therapy. Based
on these data, we view Achillion's HCV pipeline as further de-risked and look for
additional Phase II validation in 2015. Achillion ended 3Q:14 with cash of $127 million.
We reiterate our Overweight rating and $22.50 price target.
• ACH-3422 Nuc Safe and Potent. The Phase I placebo-controlled trial randomized
treatment-naïve HCV genotype 1 patients to escalating doses of 50mg, 150mg and
300mg ACH-3422 for 7 days and 500mg and 700mg ACH-3422 for 14 days of
monotherapy. Importantly, all doses were well-tolerated with no discontinuations due
to AEs, significant laboratory or ECG findings or treatment-related SAEs. The 700mg
ACH-3422 cohort showed an impressive mean max viral load reduction of 4.8 log IU/
ml with 3/6 (50%) patients at undetectable levels of HCV RNA (<10 IU/mL). We view
this as validating data that Achillion has a safe and potent nuc.
• ACH-3102 Combo Accelerates Cure. Achillion also announced interim results from
a Phase II combo study of NS5A inhibitor ACH-3102 + Gilead's nuc Sovaldi. The
combo achieved 100% (12/12) SVR4 after only 6 weeks of treatment. The reduction
was achieved independent of viral load, which was high in this cohort with 7 patients
displaying baseline HCV RNA >6 million IU/ml. The combo was well tolerated with
no discontinuations, significant lab or ECG abnormalities or SAEs. SVR12 data is
expected in 1H:15. We believe Achillion's best-in-class NS5A inhibitor ACH-3102 with
a nuc could further shorten treatment duration and cut cost vs. Gilead's HARVONI.
• Future HCV Development Plans. Based on the efficacy shown by ACH-3422 and
ACH-3102, Achillion plans to conduct the Phase II SPARTA trials in 2015 that will
feature doublets of ACH-3422 and ACH-3102, as well as triple combinations with
Achillion's protease inhibitor sovaprevir